

 <b>J P E</b> FORM PTO-1449 SEP 01 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	<b>U. S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>	<b>ATTY. DOCKET NO.</b> GNE-3230R1C23	<b>APPLICATION NO.</b> 10/083,534
		<b>APPLICANT</b> Eaton, et al.	
		<b>FILING DATE</b> May 2, 2002	<b>GROUP</b> 1647

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**EXAMINER  
INITIAL**


**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

A hand-drawn graph on lined paper. The horizontal axis (x-axis) has 10 vertical grid lines, and the vertical axis (y-axis) has 10 horizontal grid lines. A straight line is drawn from approximately (1, 2) to (9, 8), passing through points like (2, 3), (3, 4), (4, 5), (5, 6), (6, 7), and (7, 7). There is a small break in the line between x=8 and x=9.

S:\DOCS\BSG\BSG-1411.DOC  
090204

EXAMINER <u>G. Schling</u>	DATE CONSIDERED <u>9/7/04</u>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/063,534
(Multiple sheets used when necessary)		Filing Date	May 2, 2002
		First Named Inventor	Goddard, et al.
		Art Unit	1647
		Examiner	Seharaseyon, J.
		Attorney Docket No.	GNE.3230R1C23
SHEET 1 OF 2			



<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
JS	1	WO 97/38085	10-16-1997	California Pacific Medical Center		

<b>NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
JS	2	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 1216-1217. New York: Garland Publishing.				
	3	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.				
	4	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. <i>Electrophoresis</i> , 18:533-537.				
	5	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular &amp; Cellular Proteomics</i> 1, 4, pp. 304-313.				
	6	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.				
	7	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.				
	8	GÖKMEN-POLAR, et al. 2001. Elevated protein kinase C $\beta$ II is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.				
	9	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.				
	10	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.				
	11	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.				
	12	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.				
▼	13	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.				

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	09/03/2006
--------------------	---------------------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application No.</b>	<b>10/063,534</b>
		<b>Filing Date</b>	<b>May 2, 2002</b>
		<b>First Named Inventor</b>	<b>Goddard, et al.</b>
		<b>Art Unit</b>	<b>1647</b>
<i>O P E 4481 (Multiple sheets used when necessary)</i>		<b>Examiner</b>	<b>Seharaseyon, J.</b>
<b>SHEET 2 OF 2</b>		<b>Attorney Docket No.</b>	<b>GNE.3230R1C23</b>

SEP 22 2005  
PATENT & TRADEMARK OFFICE  
SEARCHED INDEXED  
SERIALIZED FILED

**NON PATENT LITERATURE DOCUMENTS**

Attala Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
JS	14	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> , 15(5):469-483. (Abstract).	
	15	KONOPKA, et al. 1986. Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	16	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.	
	17	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411-421. (Abstract).	
	18	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	
	19	VALLEJO, et al. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> , 82(12):1129-1133. (Abstract).	
	20	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

1941719  
092005

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	09/03/2006
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.